With a team of experienced scientists and executives at the helm, we bring a new way of thinking to complex drug discovery—empowering us to design novel therapeutics for unmet medical needs.
Senior Research Associate
Senior Research Associate
Office Manager/Executive Assistant
Senior Director, Chief of Staff
Director, Platform Innovation
Lab Operations Manager
Senior Director, Chemistry
Senior Principal Scientist
CEO, Navitor Pharmaceuticals
Tom Hughes has more than 30 years of industry experience in the discovery, development and commercialization of pharmaceutical products. Tom has served since 2018 as CEO of Navitor Pharmaceuticals, a privately held biopharmaceutical company.
Prior to joining Navitor, Tom served as President and Chief Scientific Officer, and earlier as CEO of Zafgen Inc. Prior to Zafgen, Tom held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research. He oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease.
Managing Partner, DCVC Bio
John is a Managing Partner at DCVC Bio. Prior to joining DCVC, John was a VP at Monsanto and Managing Director of Monsanto Growth Ventures (MGV). Before joining MGV, John was a Managing Director at Burrill & Company. Prior to his career in venture capital, John was an entrepreneur, initially at Paradigm Genetics, where he joined as a visiting scientist before becoming Chief Science Officer and eventually President and CEO following the company’s IPO. After Paradigm, John founded and served as CEO of Arête Therapeutics, which earned backing from leading life science venture firms.
Former FDA Commissioner
Most recently, Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors including serving as Managing Director, T.R. Winston & Company from 2013 to 2017. Dr. Gottlieb was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as the senior advisor to the FDA Commissioner from 2003 to 2004. Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor to the financial news network, CNBC. He also serves on the boards for Pfizer, Illumina, Aetion, and Tempus.
Director, Northpond Ventures
Shaan C. Gandhi is a Director at Northpond Ventures and leads the firm’s work in biotechnologies. Shaan is a board director at Totus Medicines, as well as several other private and public biotherapeutics companies. Previously, Shaan was a Principal at the Longwood Fund, where he created and invested in life sciences companies, including Pyxis Oncology, a cancer immunotherapy company focused on novel modulators of the tumor microenvironment, which he co-founded and served as President. Prior to Longwood, he was an attending hospitalist at Massachusetts General Hospital, where he also did his residency in internal medicine.
Partner, Camford Capital
Ali is Partner at Camford Capital, an early-stage tech and life science fund based in Palo Alto, CA. With more than 100 companies in its portfolio, Camford invests in a variety of areas in healthcare including therapeutics, diagnostics and tools, and digital health, with strong emphasis on novel mechanisms and data-driven platforms. Previously Ali worked in research and in consulting roles in semiconductor and healthcare industries. He obtained graduate degrees in engineering and management from MIT and University of Chicago.
Senior Director, Biology
John brings over 20 years of experience in diverse discovery, preclinical, and translational biology experience in oncology and immunology. Focusing his energy on small biotech companies, John has gathered an abundance of experience with a wide variety of therapeutic modalities across oncology and non-oncology disease indications and participated in advancing over ten experimental therapies into clinical trials.
Most recently, John served as Senior Director of Discovery and Translational Biology at BioXcel Therapeutics, where the team leveraged Artificial Intelligence (AI) and Machine Learning (ML) approaches to drug repurposing. Prior to this, John worked as Director of Research with Aura Biosciences, where he was responsible for scientific oversight of their novel Virus based (HPV) nanoparticle platform.
VP of Platform
Daniel Gray is the VP of Platform at Totus Medicines. Over his professional and academic career, Dan has a demonstrated leadership track record in chemical and synthetic biology with a focus on platform innovation in emerging small molecule modalities. Prior to Totus, Dan led Genome Mining at Warp Drive Bio, where he also served on the management team. Acquired by Ginkgo Bioworks in 2019, the Warp’s Genome Mining group pioneered a first-in-class genomic and synthetic biology platform for the discovery of novel natural products with new mechanisms of action.
Dan holds a PhD in Chemistry and Chemical Biology from UCSF in the lab of Jim Wells.
Chief Data Officer
John brings over 25 years of expertise in creating and leading diverse technology teams and has mentored some of the best computational scientists in the industry. Most recently, John served as the Chief Technology Officer of Kaleido Bioscience, where he created and led the new technology platform group comprising computational biology, software engineering, compound management, and lab robotics. Prior to Kaleido, he helped reshape the data and computational strategy at Novartis and developed several unique industry-leading computational approaches, which resulted in more than 100 publications across the informatics group.
John received his Ph.D. in synthetic organic chemistry from University College London before embarking on postdoctoral studies in the then-emerging field of computational chemistry at GlaxoSmithKline.
Founding Board Member & Co-founder
Jason is a founding board member of Totus Medicines. His belief that emerging technologies and new scientific insights can solve urgent challenges and expand human possibilities inspires his investments in Deep Tech and life sciences companies. Most recently, he served as a senior partner and advisor at Flagship Pioneering in Cambridge, MA, where he worked with the enterprise’s therapeutics and agriculture companies. Jason has written for a range of publications including a column for the New York Times and articles for many other newspapers and magazines like WIRED, The Economist, The Financial Times, The Boston Globe and The Believer.
Senior Director, Chemical Biology & Co-founder
Jimmy is the scientific co-founder and Head of Chemical Biology at Totus Medicines, where he pioneered the Totus hit generation engine and leads the discovery chemistry and screening team. His research is steeped in covalency, including development of novel covalent molecules for protein kinases and synthesis of covalent inhibitors for neglected diseases. Prior to Totus, Jimmy contributed to chemical biology and metabolomics efforts at Jnana Therapeutics, and he was a faculty member at Williams College, where he led an undergraduate team in the pursuit of novel antibiotics.
Jimmy holds a PhD in Chemistry from UC Berkeley in Kevan Shokat’s lab and was a postdoctoral fellow at Stanford University in Lucy Shapiro’s lab.
CEO & Co-founder
Neil Dhawan is the Founder and CEO of Totus Medicines, where he focuses on combining small molecule design, structural biology, genetics, biochemistry, and cell biology to design new classes of drugs to target untreatable diseases. Prior to founding Totus Medicines, Neil co-founded Dual Therapeutics, a venture-backed biotechnology company developing the first phosphatase agonists for cancer patients. Neil co-invented and helped develop the lead drug program, small molecule agonists of PP2A, which led to a collaboration deal with Bristol Myers Squibb valued at up to $225 million.
Previously, Neil developed the first rational drug discovery approach to target pseudokinases, a class of ‘undruggable’ targets with broad roles in cancer, diabetes, Alzheimer’s disease, and aging.
Totus Medicines is looking for brilliant minds to help us bring our vision to life. Shaping the future of chemical biology isn’t a small endeavor. It takes a multidisciplinary team with relentless drive.
Our life’s work is
to save lives.